Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Psychoneuroendocrinology ; 132: 105345, 2021 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1284482

RESUMEN

Loneliness is associated with multiple forms of psychopathology in youth. However, we do not yet know how loneliness gets "under the skin" in ways that may impact the long-term health and development of early adolescents. In particular, loneliness may influence youths' patterns of diurnal cortisol, an index of hypothalamic-pituitary-adrenal (HPA) axis functioning and a central predictor of health across the lifespan. The current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, or COVID-19) pandemic represents a salient period in which to study the consequences of loneliness, as recent work has provided evidence that the physical-distancing measures put in place to contain the virus have resulted in greater loneliness, particularly among youth. Thus, the current study aimed to examine the prospective association between loneliness during the COVID-19 pandemic and diurnal cortisol in early adolescents. We found that greater loneliness was associated with higher levels of cortisol at waking and a blunted cortisol awakening response (CAR). These results held even when controlling for covariates that can influence diurnal trajectories of cortisol. Critically, this pattern of HPA-axis functioning increases risk for adverse mental and physical health outcomes across adolescence and into adulthood. This study is the first to examine the prospective association between loneliness and diurnal cortisol in early adolescence, and the first to identify mechanisms that contribute to biological markers of distress during the COVID-19 pandemic. Findings underscore the importance of developing and distributing strategies to mitigate feelings of loneliness among youth.


Asunto(s)
COVID-19 , Ritmo Circadiano , Hidrocortisona/metabolismo , Sistema Hipotálamo-Hipofisario/metabolismo , Soledad/psicología , Sistema Hipófiso-Suprarrenal/metabolismo , Adolescente , Femenino , Humanos , Hidrocortisona/análisis , Masculino , Pruebas de Función Adreno-Hipofisaria , SARS-CoV-2 , Saliva/química
2.
J Clin Endocrinol Metab ; 106(8): 2208-2220, 2021 07 13.
Artículo en Inglés | MEDLINE | ID: covidwho-1234575

RESUMEN

CONTEXT: The COVID-19 pandemic continues to exert an immense burden on global health services. Moreover, up to 63% of patients experience persistent symptoms, including fatigue, after acute illness. Endocrine systems are vulnerable to the effects of COVID-19 as many glands express the ACE2 receptor, used by the SARS-CoV-2 virion for cellular access. However, the effects of COVID-19 on adrenal and thyroid gland function after acute COVID-19 remain unknown. OBJECTIVE: Our objectives were to evaluate adrenal and thyroid gland function in COVID-19 survivors. METHODS: A prospective, observational study was undertaken at the Clinical Research Facility, Imperial College NHS Healthcare Trust, including 70 patients ≥18 years of age, at least 3 months after diagnosis of COVID-19. Participants attended a research study visit (8:00-9:30 am), during which a short Synacthen test (250 µg IV bolus) and thyroid function assessments were performed. RESULTS: All patients had a peak cortisol ≥450 nmol/L after Synacthen, consistent with adequate adrenal reserve. Basal and peak serum cortisol did not differ according to disease severity or history of dexamethasone treatment during COVID-19. There was no difference in baseline or peak cortisol after Synacthen or in thyroid function tests, or thyroid status, in patients with fatigue (n = 44) compared to those without (n = 26). CONCLUSION: Adrenal and thyroid function ≥3 months after presentation with COVID-19 was preserved. While a significant proportion of patients experienced persistent fatigue, their symptoms were not accounted for by alterations in adrenal or thyroid function. These findings have important implications for the clinical care of patients after COVID-19.


Asunto(s)
Glándulas Suprarrenales/fisiología , COVID-19/rehabilitación , Glándula Tiroides/fisiología , Adulto , Anciano , COVID-19/sangre , COVID-19/epidemiología , Estudios de Cohortes , Dexametasona/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Hidrocortisona/sangre , Masculino , Persona de Mediana Edad , Pandemias , Pruebas de Función Adreno-Hipofisaria , Estudios Prospectivos , SARS-CoV-2/fisiología , Sobrevivientes/estadística & datos numéricos , Pruebas de Función de la Tiroides , Hormonas Tiroideas/sangre , Tirotropina/sangre , Reino Unido/epidemiología , Tratamiento Farmacológico de COVID-19
3.
BMJ Case Rep ; 14(1)2021 Jan 18.
Artículo en Inglés | MEDLINE | ID: covidwho-1066835

RESUMEN

SARS-CoV-2 is the cause of COVID-19. Since the outbreak and rapid spread of COVID-19, it has been apparent that the disease is having multi-organ system involvement. Still its effect in the endocrine system is not fully clear and data on cortisol dynamics in patients with COVID-19 are not yet available. SARS-CoV-2 can knock down the host's cortisol stress response. Here we present a case of a 51-year-old man vomiting for 10 days after having confirmed COVID-19 infection. He had hypotension and significant hyponatraemia. Work-up was done including adrenocorticotropic hormone stimulation test. He was diagnosed as suffering from adrenal insufficiency and started on steroids with subsequent improvement in both blood pressure and sodium level. COVID-19 can cause adrenal insufficiency. Clinicians must be vigilant about the possibility of an underlying relative cortisol deficiency in patients with COVID-19.


Asunto(s)
Insuficiencia Suprarrenal/fisiopatología , COVID-19/fisiopatología , Hiponatremia/fisiopatología , Hipotensión/fisiopatología , Acidosis/sangre , Acidosis/fisiopatología , Acidosis/terapia , Insuficiencia Suprarrenal/sangre , Insuficiencia Suprarrenal/diagnóstico , Insuficiencia Suprarrenal/tratamiento farmacológico , COVID-19/sangre , Fluidoterapia , Glucocorticoides/uso terapéutico , Humanos , Hidrocortisona/sangre , Hiponatremia/sangre , Hiponatremia/terapia , Hipofosfatemia/sangre , Hipofosfatemia/fisiopatología , Hipofosfatemia/terapia , Hipotensión/terapia , Masculino , Persona de Mediana Edad , Pruebas de Función Adreno-Hipofisaria , Prednisolona/uso terapéutico , SARS-CoV-2 , Vómitos/fisiopatología , Desequilibrio Hidroelectrolítico/sangre , Desequilibrio Hidroelectrolítico/fisiopatología , Desequilibrio Hidroelectrolítico/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA